Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
前收盤價
US$8.60
−US$0.12 · -1.38%
盤中時間採用ET。市場資料可能有所延遲。
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
日內區間
目前US$8.60
52週區間
目前US$8.60
盤中時間採用ET。市場資料可能有所延遲。
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
日內區間
目前US$8.60
52週區間
目前US$8.60
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.02億 USD | 6204.3萬 USD | 1.54億 USD | 6777.2萬 USD | 6188萬 USD |
| 銷貨成本 | 732.4萬 USD | 721.8萬 USD | 681.6萬 USD | 828.8萬 USD | 977.3萬 USD |
| 毛利 | 9516萬 USD | 5482.5萬 USD | 1.47億 USD | 5948.4萬 USD | 5210.7萬 USD |
| 研究與開發 | 1.66億 USD | 2.52億 USD | 1.8億 USD | 1.37億 USD | 1.04億 USD |
| 銷售、一般及管理費用 | 4101.9萬 USD | 4845.3萬 USD | 6258.4萬 USD | 5954.4萬 USD | 5600.4萬 USD |
| 營業費用 | 2億 USD | 2.93億 USD | 2.36億 USD | 1.88億 USD | 1.51億 USD |
| 利息收入 | 925.1萬 USD | 4442.5萬 USD | 1451萬 USD | 345.5萬 USD | 57.7萬 USD |
| 利息支出 | 3820.8萬 USD | 3107萬 USD | 2375萬 USD | 334.6萬 USD | 313.7萬 USD |
| 折舊和攤銷 | 732.4萬 USD | 721.8萬 USD | 681.6萬 USD | 569萬 USD | 484.4萬 USD |
| 營業利益 | −1.05億 USD | −2.38億 USD | −8927.8萬 USD | −1.29億 USD | −9852.4萬 USD |
| 淨利 | −1.91億 USD | −2.27億 USD | −1.07億 USD | −1.19億 USD | −1.06億 USD |
公司資料更新於 2026年11月22日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI339.85萬0.00%6893億 USD0.03%US$340.02-3.52%
iShares Russell 2000 ETFIWM334.24萬0.00%715.37億 USD0.19%US$256.61-2.88%
Fidelity Enhanced Small Cap ETFFESM145.57萬0.02%67.4億 USD0.28%US$41.85-2.49%
Vanguard Extended Market ETFVXF145.47萬0.00%302億 USD0.05%US$211.44-3.21%
Vanguard U.S. Momentum Factor ETFVFMO131.78萬0.07%19億 USD0.13%US$193.88-3.13%
iShares Russell 2000 Value ETFIWN98.29萬0.01%130.46億 USD0.24%US$198.84-2.08%
Vanguard Russell 2000 ETFVTWO76.95萬0.00%168億 USD0.06%US$103.76-2.76%
Vanguard Health Care ETFVHT41.69萬0.00%208億 USD0.09%US$326.69-0.40%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Fidelity Enhanced Small Cap ETFFESM
Vanguard Extended Market ETFVXF
Vanguard U.S. Momentum Factor ETFVFMO
iShares Russell 2000 Value ETFIWN
Vanguard Russell 2000 ETFVTWO
Vanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。